公开(公告)号：US20240076396A1

公开(公告)日：2024-03-07

申请号：US18461760

申请日：2023-09-06

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Robert Babb ,  Drew Dudgeon ,  Yu Huang ,  Rosalynn Molden ,  William Olson ,  Matthew Sleeman ,  Dimitris Skokos ,  Bei Wang

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

公开(公告)号：US20230089727A1

公开(公告)日：2023-03-23

申请号：US17946757

申请日：2022-09-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Xiaoxiao Huang ,  Yu Huang ,  Xiaojing Zheng ,  Ning Li

IPC: G01N33/68 ,  G01N30/72 ,  G01N30/88 ,  G01N30/86

Abstract: The present invention generally pertains to methods of characterizing at least one protein of interest in a biological sample. In particular, the present invention pertains to the use of automated iterative tandem mass spectrometry (AIMS) to identify, quantify and characterize at least one protein of interest and/or biomarker from a biological sample such as plasma.

公开(公告)号：US20220367001A1

公开(公告)日：2022-11-17

申请号：US17824098

申请日：2022-05-25

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Xiaobin Xu ,  Yu Huang

IPC: G16B5/20 ,  G06F17/11 ,  G01N33/68

Abstract: Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.

公开(公告)号：US20220155317A1

公开(公告)日：2022-05-19

申请号：US17528432

申请日：2021-11-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Yu Huang ,  Mengqi Hu ,  Haibo Qiu

IPC: G01N33/68 ,  G01N30/72 ,  G01N30/86

Abstract: The present disclosure generally pertains to methods of identifying and quantitating host cell proteins (HCPs) in therapeutic protein development. In particular, the present invention generally pertains to methods of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for unbiased identification and sensitive quantitation of HCPs in therapeutic protein development.

公开(公告)号：US20190237157A1

公开(公告)日：2019-08-01

申请号：US16264044

申请日：2019-01-31

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Xiaobin Xu ,  Yu Huang

IPC: G16B5/20 ,  G06F17/11

CPC classification number: G16B5/20 ,  C07K16/00 ,  C07K2317/00 ,  G01N33/6842 ,  G01N33/6854 ,  G01N2440/00 ,  G06F17/11 ,  G16B20/20

Abstract: Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.

公开(公告)号：US20250035643A1

公开(公告)日：2025-01-30

申请号：US18916242

申请日：2024-10-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Haibo Qiu ,  Yu Huang ,  Mengqi Hu

IPC: G01N33/68 ,  G01N30/02 ,  G01N30/72 ,  G01N30/86 ,  H01J49/00

Abstract: The present disclosure generally pertains to methods of identifying and quantitating host cell proteins (HCPs) in therapeutic protein development. In particular, the present invention generally pertains to methods of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for unbiased identification and sensitive quantitation of HCPs in therapeutic protein development.

公开(公告)号：US12153053B2

公开(公告)日：2024-11-26

申请号：US17528432

申请日：2021-11-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Haibo Qiu ,  Yu Huang ,  Mengqi Hu

IPC: G01N30/72 ,  G01N30/68 ,  G01N30/86 ,  G01N33/68 ,  H01J49/00 ,  G01N30/02

Abstract: The present disclosure generally pertains to methods of identifying and quantitating host cell proteins (HCPs) in therapeutic protein development. In particular, the present invention generally pertains to methods of liquid chromatography-tandem mass spectrometry (LC-MS/MS) for unbiased identification and sensitive quantitation of HCPs in therapeutic protein development.

公开(公告)号：US11787867B2

公开(公告)日：2023-10-17

申请号：US17193586

申请日：2021-03-05

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Robert Babb ,  Drew Dudgeon ,  Yu Huang ,  Rosalynn Molden ,  William Olson ,  Matthew Sleeman ,  Dimitris Skokos ,  Bei Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76

Abstract: Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (GITR), compositions comprising the antibodies or antigen-binding fragments thereof, and methods of using the same, including, e.g., methods of treatment using the same.

公开(公告)号：US20230279046A1

公开(公告)日：2023-09-07

申请号：US18114047

申请日：2023-02-24

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Hui Xiao ,  Ning Li ,  Bo Zhao ,  Haruna Tomono ,  Mengqi Hu ,  Rosalynn Molden ,  Yunli Hu ,  Yu Huang ,  Haibo Qiu

IPC: C07K1/22 ,  C07K1/36

CPC classification number: C07K1/22 ,  C07K1/36

Abstract: The present invention generally pertains to methods of identifying and characterizing host cell proteins. In particular, the present invention pertains to the use of size exclusion chromatography in non-denaturing or denaturing conditions to enrich a sample for host cell proteins and characterize the binding of host cell proteins to a protein of interest.

公开(公告)号：US11355217B2

公开(公告)日：2022-06-07

申请号：US16264044

申请日：2019-01-31

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Xiaobin Xu ,  Yu Huang

IPC: G01N33/48 ,  G01N33/50 ,  G16B5/20 ,  G06F17/11 ,  G01N33/68 ,  C07K16/00 ,  G16B20/20

Abstract: Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.